Your local clinical sales specialist can provide education on ARCALYST.

REQUEST TO SPEAK TO A CLINICAL SALES SPECIALIST

Please complete the form below so your Clinical Sales Specialist can follow up with you directly.

All fields required.

First Name

Last Name

Phone

Email

Zip code

NPI Number

Yes

No

Specialty

Institution or Organization

YES, I would like to be contacted by a Kiniksa Clinical Sales Specialist to learn more about ARCALYST.

YES, I would like to receive updates regarding new materials on recurrent pericarditis.

By clicking “Submit,” I agree that Kiniksa may use the information I’m submitting to provide me with information I requested and other related information, including services or programs that Kiniksa offers or sponsors, or other topics of interest. I understand that all personal information I have submitted will be used only in accordance with Kiniksa’s privacy policy, and I agree to Kiniksa’s terms of use.

Request to speak to a Clinical Sales Specialist

Indication

ARCALYST^® (rilonacept) is an interleukin-1 blocker indicated for:

Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older.
Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older.
Maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more.

Important Safety Information

Warnings and Precautions

Interleukin-1 (IL-1) blockade may interfere with the immune response to infections. Treatment with another medication that works through inhibition of IL-1 or inhibition of tumor necrosis factor (TNF) is not recommended as this may increase the risk of serious infection. Serious, life-threatening infections have been reported in patients taking ARCALYST. Do not initiate treatment with ARCALYST in patients with an active or chronic infection.
Discontinue ARCALYST if a patient develops a serious infection.
It is possible that taking drugs such as ARCALYST that block IL-1 may increase the risk of tuberculosis (TB) or other atypical or opportunistic infections.
Although the impact of ARCALYST on infections and the development of malignancies is not known, treatment with immunosuppressants, including ARCALYST, may result in an increase in the risk of malignancies.
Hypersensitivity reactions associated with ARCALYST occurred in clinical trials. Discontinue ARCALYST and initiate appropriate therapy if a hypersensitivity reaction occurs.
Increases in non-fasting lipid profile parameters occurred in patients treated with ARCALYST in clinical trials. Patients should be monitored for changes in their lipid profiles.
Since no data are available, avoid administration of live vaccines while patients are receiving ARCALYST. ARCALYST may interfere with the normal immune response to new antigens, so vaccines may not be effective in patients receiving ARCALYST. It is recommended that, prior to initiation of therapy with ARCALYST, patients receive all recommended vaccinations, as appropriate.

Adverse Reactions

In patients with CAPS or RP, the most common adverse reactions (≥10%) include injection-site reactions and upper respiratory tract infections.
In patients with DIRA, the most common adverse reactions (>10%) include upper respiratory tract infections, rash, otitis media, pharyngitis, and rhinorrhea.

Drug Interactions

In patients being treated with CYP450 substrates with narrow therapeutic indices, therapeutic monitoring of the effect or drug concentration should /pi.pdfbe performed, and the individual dose of the medicinal product may need to be adjusted.

For more information about ARCALYST, see full Prescribing Information.

✕

Continue Go Back